摘要
西格列汀作为二肽基肽酶-4抑制剂中最早在中国上市的药物,单用或与其他药物联合使用均可安全有效地改善血糖,且具有低血糖风险小及不易增加患者体重等优势。除降糖作用外,西格列汀还具有心血管保护及改善微血管病变等作用。本文旨在对西格列汀治疗2型糖尿病的国内外研究现状作一综述。
Sitagliptin as the earliest dipeptidyl peptidase-4inhibitor marketed in China,when used alone or in combination with other drugs,can safely and effectively improve blood glucose,with little risk of hypoglycemia and weight gain among the patients.In addition to its hypoglycemic effect,sitagliptin also has the effects of cardiovascular protection and improvement of microvascular disease.This paper aims to review the current research status of sitagliptin in the treatment of type2diabetes mellitu
作者
陈俊
齐昊
CHEN Jun;QI Hao(Department of Endocrinology,the First Hospital of Shanxi Medical University,Taiyuan 030001,China)
出处
《中华临床医师杂志（电子版）》
CAS
2017年第16期2149-2151,共3页
Chinese Journal of Clinicians(Electronic Edition)
基金
太原市科学技术局社会发展基金项目(11027606)
关键词
西格列汀
糖尿病
血糖波动
Sitagliptin
Diabetes mellitus
Blood glucose variability
